Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal and age-related interstitial lung disease whose etiology and pathogenesis are still largely unknown. It is important to identify IPF patients at high risk of mortality so that early appropriate treatment can improve their prognosis. Therefore, the investigation of available and reliable prognostic biomarkers for IPF is crucial.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Chronic pain
Nano-ECS modulator Adezunap improves therapy success
- Psoriasis and PsA
Biologics, oral peptide and trivalent nanobody – current results and trends
- Cancer in Europe: facts and analysis
New Health Policy Report published
- Gastrointestinal complaints
PPI regulation under the microscope
- Wound management: clinical diagnostics
Assessing the risk of infection – from the ABCDE to the TILI score
- Study report
Digital patient education for atrial fibrillation shows measurable effects
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Important basics and studies on cancer and the psyche